- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01273948
Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection
A Randomized, Active-Control Phase II Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 Infection
This will be a randomized, open-label, active-control Phase II pilot trial of bavituximab combined with ribavirin for initial treatment of chronic HCV genotype 1 infection. Eligible patients with normal coagulation, hematological, and renal function will undergo a screening/washout period of up to 28 days, followed by randomization to receive weekly bavituximab or PEG-IFN alpha-2a therapy for 12 weeks, both with twice-daily ribavirin.
The primary endpoint of this study is the proportion of patients who show a greater than or equal to 2-log10 IU reduction in plasma HCV RNA level after 12 weeks of treatment (early virological response; EVR).
Secondary endpoints include the proportion of patients with an undetectable HCV RNA level after 12 weeks of treatment; the proportion of patients who show a reduction in HCV RNA level of greater than or equal to 2 log10 IU after 4 weeks of treatment, viral kinetics for individual patients over time, and comprehensive evaluation of the safety and tolerability of bavituximab infusion.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Tbilisi, Georgia
- LTD Vakhtang Bochorishvili Anticeptic Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female between the ages of 18 and 65 years
- Chronic hepatitis C virus (HCV) genotype 1 infection
- HCV RNA level >10,000 IU/mL
Chronic HCV infection, defined as:
- Previous documentation of positive HCV serology (HCV antibody or RNA) at least 6 months (24 weeks) previously, or
- Positive HCV serology (HCV antibody or RNA) with a prior remote (more than 6 months previously) risk factor for acquisition of HCV or
- Historical biopsy consistent with chronic HCV infection
No clinically significant abnormalities in hematology, coagulation, or chemistry variables:
- Hemoglobin >12 g/dL for women; >13 g/dL for men
- Total white cell count >3000/mm3 and absolute neutrophil count >1500/mm3
- Platelets >100,000/mm3
- Prothrombin time (PT) and/or international normalized ratio (INR) less than or equal to 1.2 times the local upper limit of normal (ULN)
- Conjugated (direct) bilirubin less than or equal to 1.5 times the ULN
- Serum creatinine within normal limits
- Thyroid-stimulating hormone (TSH) and free thyroxine (T4) within normal limits
- Female patients: negative urine pregnancy test
- Ability to provide informed consent
Exclusion Criteria:
- Previous interferon-based antiviral therapy for chronic HCV infection
- Previous treatment with known immunogenic drugs
- Concomitant human immunodeficiency (HIV) or hepatitis B virus (HBV) infection
- Cause of liver disease other than chronic HCV infection, such as autoimmune or alcoholic liver disease
- Decompensated clinical liver disease, including a history of encephalopathy, bleeding esophageal or gastric varices, or ascites
- Recipient of liver or other solid-organ transplantation
- Evidence of clinically significant bleeding, defined as gross hematuria, hemoptysis, or gastrointestinal bleeding
- History of bleeding diathesis or coagulopathy (eg, von Willebrand disease or hemophilia)
- History of thromboembolic events (eg, deep-vein thrombosis [DVT] or pulmonary embolism). Previous central venous catheter-related thrombosis is acceptable if there is resolution recorded at least 12 months before enrollment.
- Requirement for concurrent treatment with oral or parenteral anticoagulants or hormones (estrogen-containing contraceptives, hormone replacement, antiestrogen agents, progestins)
- Condition requiring daily therapy with antiplatelet agents (eg, thienopyridines, dipyridamole, cilostazol; cardiovascular prophylaxis with aspirin is allowed) or corticosteroids
- Investigational therapy within 28 days before the first planned dose of study drug
- Major surgery within 28 days before the first planned dose of study drug
- Uncontrolled intercurrent disease (eg, diabetes, hypertension, thyroid disease)
- Ongoing angina pectoris or other symptoms of coronary artery disease (CAD); history of stroke, or transient ischemic attack (TIA)
- History of suicidal ideation or attempt
- Condition requiring treatment (past or current) with coumarin-type agents
- Cardiac arrhythmia requiring medical therapy
- Serious nonhealing wound (including wound healing by secondary intention, ulcer, or bone fracture)
- Cancer, autoimmune disease, or any disease or concurrent therapy known to cause significant alteration in immune function (corticosteroids are allowed before study enrollment and during the study to treat an AE)
- Female patients and female partners of male patients: pregnancy, lactation, or inability/unwillingness to practice effective contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Bavituximab 3 mg/kg
Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
|
Other Names:
|
EXPERIMENTAL: Bavituximab 0.3 mg/kg
Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
|
Other Names:
|
ACTIVE_COMPARATOR: Pegylated interferon (PEG-IFN)
Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
|
Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Hepatitis C Virus RNA
Time Frame: 12 weeks
|
The primary endpoint is the proportion of patients who show a greater or equal 2-log(10) IU reduction in HCV RNA level at Study Week 12 (early virological response, EVR).
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Janet Nuttall, MPH, Peregrine Pharmaceuticals
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis
- Hepatitis C
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Interferons
- Bavituximab
Other Study ID Numbers
- PPHM 1003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
University Health Network, TorontoCompletedChronic Hepatitis C InfectionCanada
Clinical Trials on Bavituximab
-
Peregrine PharmaceuticalsCompleted
-
Peregrine PharmaceuticalsWithdrawn
-
Peregrine PharmaceuticalsCompletedHepatitis C Virus | Hiv InfectionsUnited States
-
Medical University of South CarolinaPeregrine PharmaceuticalsTerminatedProstatic Neoplasms | Prostate CancerUnited States
-
Peregrine PharmaceuticalsCompletedCarcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small-Cell Lung Carcinoma | Non-Small-Cell Lung Cancer Stage IIIB | Non-Small-Cell Lung Cancer Stage IV | Non-Small-Cell Lung Cancer MetastaticUnited States, Australia, Belgium, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Romania, Russian Federation, Spain, Taiwan, Ukraine
-
University of Texas Southwestern Medical CenterCompletedHepatocellular Carcinoma | Liver CancerUnited States
-
Peregrine PharmaceuticalsCompletedNon-small-cell Lung CancerUnited States, India, Georgia, Russian Federation, Ukraine
-
BayerCompleted
-
Peregrine PharmaceuticalsCompleted
-
Peregrine PharmaceuticalsCompletedNon-Squamous Non-Small Cell Lung CancerUnited States, India, Georgia, Russian Federation, Ukraine